nimodipine Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1937 66085-59-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nimodipine
  • nemotan
  • nymalize
A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
  • Molecular weight: 418.45
  • Formula: C21H26N2O7
  • CLOGP: 4
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 117
  • ALOGS: -4.54
  • ROTB: 10

Drug dosage:

DoseUnitRoute
0.30 g O
50 mg P

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1988 FDA

FDA Adverse Event Reporting System

None

Pharmacologic Action:

SourceCodeDescription
ATC C08CA06 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35554 cardiovascular drug
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
FDA Chemical/Ingredient N0000007556 Dihydropyridines

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Subarachnoid intracranial hemorrhage indication 21454007
Essential tremor off-label use 609558009 DOID:4990
Low blood pressure contraindication 45007003
Chronic idiopathic constipation contraindication 82934008
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.09 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
60MG/20ML NYMALIZE ARBOR PHARMS LLC N203340 May 10, 2013 RX SOLUTION ORAL May 10, 2020 IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel BLOCKER UNKNOWN CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER UNKNOWN CHEMBL
Cytochrome P450 2C9 Enzyme IC50 6 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 5.40 DRUG MATRIX
Sodium/nucleoside cotransporter 1 Transporter Ki 6.36 DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 5.25 WOMBAT-PK
Adenosine receptor A3 GPCR Ki 5.07 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Ki 6.12 WOMBAT-PK
Mineralocorticoid receptor Nuclear hormone receptor ANTAGONIST IC50 6.80 IUPHAR
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor EC50 6.41 CHEMBL
Bile acid receptor Nuclear hormone receptor IC50 5.05 CHEMBL
Voltage-dependent calcium channel gamma-1 subunit Ion channel WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1F Ion channel GATING INHIBITOR IC50 6 IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel GATING INHIBITOR IC50 6 IUPHAR
Cannabinoid receptor 1 GPCR Ki 5.86 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 4.35 CHEMBL
Adenosine receptor A1 GPCR Ki 4.70 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel GATING INHIBITOR IC50 6.80 IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel GATING INHIBITOR IC50 6.60 IUPHAR

External reference:

IDSource
DB00393 DRUGBANK_ID
2523 IUPHAR_LIGAND_ID
4019390 VUID
N0000147543 NUI
C0028094 UMLSCUI
D00438 KEGG_DRUG
57WA9QZ5WH UNII
4528 INN_ID
4019390 VANDF
7426 RXNORM
387502003 SNOMEDCT_US
87285001 SNOMEDCT_US
5177 MMSL
N0000006560 NDFRT
N0000147543 NDFRT
000713 NDDF
109672 MMSL
d00318 MMSL
CHEMBL1428 ChEMBL_ID
CHEMBL255033 ChEMBL_ID
4497 PUBCHEM_CID
D009553 MESH_DESCRIPTOR_UI
CHEBI:7575 CHEBI
6U9 PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6566 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 14 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 23155-108 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 13 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 23155-512 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 13 sections
Nymalize HUMAN PRESCRIPTION DRUG LABEL 1 24338-200 SOLUTION 60 mg ORAL NDA 17 sections
Nymalize HUMAN PRESCRIPTION DRUG LABEL 1 24338-205 SOLUTION 30 mg ORAL NDA 17 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 55154-4184 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 13 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 57664-135 CAPSULE 30 mg ORAL ANDA 13 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 62559-210 CAPSULE 30 mg ORAL ANDA 13 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 63739-797 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 14 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 67877-297 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 14 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 68084-912 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 14 sections
Nimodipine HUMAN PRESCRIPTION DRUG LABEL 1 69452-209 CAPSULE, LIQUID FILLED 30 mg ORAL ANDA 13 sections